Dose-dense therapy in the treatment of early-stage breast cancer: An overview of the data

Clinical Breast Cancer

Volumn 8, Issue SUPPL. 1, 2007, Pages S6-

  McArthur, Heather L ^a   Hudis, Clifford A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adjuvant chemotherapy; Cyclophosphamide; Doxorubicin; Paclitaxel

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE;

ADJUVANT THERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RESEARCH; CARDIOTOXICITY; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG DOSE SEQUENCE; FEBRILE NEUTROPENIA; HUMAN; LEUKEMIA; MULTIPLE CYCLE TREATMENT; NEOPLASM; NEUROTOXICITY; REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME; UNITED STATES;

EID: 38849153725     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2007.s.007     Document Type: Article

References (20)

1. American Cancer Society [Web site]. WHO World Cancer Report. Available at: http://www.cancer.org. Lyon, France: World Health Organization; 2003.
2. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353:1784-92.
3. Elkin EB, Hurria A, Mitra N, et al. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol 2006; 24:2757-64.
4. Norton L, Simon R, Brereton HD, et al. Predicting the course of Gompertzian growth. Nature 1976; 264:542-5.
5. Norton L. A Gompertzian model of human breast cancer growth. Cancer Res 1988; 48:7067-71.
6. Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 1995; 273:542-7.
7. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21:1431-9.
8. Hudis C. Dose-dense adjuvant chemotherapy for breast cancer. In: American Society of Clinical Oncology; 2005; Orlando, FL; 2005.
9. Venturini M, Aitini E, Del Mastro L, et al. Phase III adjuvant trial comparing standard versus accelerated FEC regimen in early breast cancer patients. Results from GONO - M1G1 study. Breast Cancer Res Treat 2003; 82(suppl 1):S9 (Abstract 12).
10. Venturini M, Del Mastro L, Aitini E, et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst 2005; 97:1724-33.
11. Möbus V, Untch M, Bois AD, et al. Dose-dense sequential chemotherapy with epirubicin(E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (≥ 4 +LN). First results of an AGO-trial. Presented at: the 40th Annual Meeting of the American Society of Clinical Oncology; June 5-8, 2004; New Orleans, LA. Abstract 513.
12. Moebus VJ, Leuck HJ, Thomssen C, et al. Dose-dense sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC) in comparison to conventional schedule chemotherapy in high-risk breast cancer patients (≥ 4+ LN). Mature results of an AGO-trial. Breast Cancer Res Treat 2006; 100(suppl 1):S20 (Abstract 43).
13. Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol 2003; 21:843-50.
14. Burnell M, Levine M, Chapman JA, et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Presented at: 29th Annual San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, TX.
15. Sparano J, Wang M, Martino S, et al. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every three weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199. Presented at: 28th San Antonio Breast Cancer Symposium; December 8-11, 2005; San Antonio, TX. Abstract 48.
16. Sparano JA, Wang M, Martino S, et al. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: results of Intergroup Trial E1199. J Clin Oncol 2007; 25(18 suppl):6s (Abstract 516).
17. Puhalla S, Young D, Ottman S, et al. Phase II randomized adjuvant trial of dose-dense docetaxel (DOC) before or after doxorubicin/cyclophosphamide (AC) in axillary node-positive breast cancer. Breast Cancer Res Treat 2006; 100:S115-6 (Abstract 2104).
18. Ellis GK, Green SJ, Russell CA, et al. SWOG 0012, a randomized phase III comparison of standard doxorubicin and cyclophosphamide followed by weekly paclitaxel versus weekly doxorubicin and daily oral cyclophosphamide plus G-CSF followed by weekly paclitaxel as neoadjuvant therapy for inflammatory and locally advanced breast cancer. J Clin Oncol 2006; 24(18 suppl):12s (LBA 537).
19. Dang C, Smith K, Fornier M, et al. Mature cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA). Breast Cancer Res Treat 2006; 100(suppl 1):S114-5 (Abstract 2101).
20. Sugarman SM, Wasserheit C, Hodgman E, et al. A pilot study of growth factor (GF) omission during paclitaxel (T) for women with early breast carcinoma (BC). Breast Cancer Res Treat 2006; 100(suppl 1):S284 (Abstract 6084).